April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
IgG Remodeling In The Eye: A Role For The Neonatal Fc Receptor?
Author Affiliations & Notes
  • Kiki van Bilsen
    Internal Dept/Clinical Immunol,
    Erasmus MC, Rotterdam, The Netherlands
    The Rotterdam Eye Hospital, Rotterdam, The Netherlands
  • P M. van Hagen
    Internal Dept/Clinical Immunol,
    Erasmus MC, Rotterdam, The Netherlands
    The Rotterdam Eye Hospital, Rotterdam, The Netherlands
  • J Bastiaans
    Immunology,
    Erasmus MC, Rotterdam, The Netherlands
    The Rotterdam Eye Hospital, Rotterdam, The Netherlands
  • S G. Baarsma
    The Rotterdam Eye Hospital, Rotterdam, The Netherlands
  • R W. Kuijpers
    Ophthalmology,
    Erasmus MC, Rotterdam, The Netherlands
  • W A. Dik
    Immunology,
    Erasmus MC, Rotterdam, The Netherlands
  • Footnotes
    Commercial Relationships  Kiki van Bilsen, None; P. M. van Hagen, None; J. Bastiaans, None; S. G. Baarsma, None; R. W. Kuijpers, None; W. A. Dik, None
  • Footnotes
    Support  SWOO-Flieringa grant 2008-05
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 2920. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kiki van Bilsen, P M. van Hagen, J Bastiaans, S G. Baarsma, R W. Kuijpers, W A. Dik; IgG Remodeling In The Eye: A Role For The Neonatal Fc Receptor?. Invest. Ophthalmol. Vis. Sci. 2011;52(14):2920.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Data concerning IgG metabolism and transport in the eye is scarse. However, recent new therapies with monoclonal antibodies, interpretation of the Goldmann-Wittmer coefficient (GWC) and the role of IgG in drusen warrant more studies to understand intraocular IgG processing. An important role for IgG remodeling is assigned to the neonatal Fc receptor (FcRn). Recently, we found that RPE cells express FcRn. Since the blood retina barrier consists not only of RPE cells but also of endothelial cells, we investigated expression and regulation of FcRn by human retinal endothelial cells (HRMVECs). Moreover, we studied FcRn expression by human immune cells which play an important role in inflammatory retinal diseases.

Methods: : HRMVECs were purchased from Applied Cell Biology Research Institute (Kirkland, WA) and dermal endothelial cells, HMEC-1 cell lines were purchased from ATCC. Lymphocyte subsets were sorted from freshly harvested PBMCs from three healthy donors. FcRn and β2M mRNA levels were determined by RQ-PCR. Protein expression was determined by Western blot. Stimulation assays were performed with human TNF-alpha.

Results: : Both HRMVEC and HMEC-1 cells express FcRn. However, FcRn expression in the retinal endothelium is downregulated by TNF-alpha, whereas FcRn expression in the dermal endothelium is upregulated by TNF-alpha. Both human B and T lymphocytes and monocytes express FcRn as well. Results of stimulation assays with human lymphocytes are pending.

Conclusions: : HRMVEC cells express FcRn and this can be downregulated by TNF-alpha, similar to regulation in RPE cells. This is in contrast to FcRn regulation in periferal endothelial and epithelial cells. We also found FcRn expression in selected human immune cells, which may have implications for IgG remodelling in inflammatory retinal diseases. FcRn might well be an important factor in IgG transport over the blood retina barrier.

Keywords: immunomodulation/immunoregulation • immune tolerance/privilege • retinal pigment epithelium 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×